Darren J Kelly

List of Publications by Year in descending order

209 papers	11,140 citations	20817 60 h-index	39675 94 g-index
211 all docs	211 docs citations	211 times ranked	11960 citing authors

#	Article	IF	Citations
1	NP202 treatment improves left ventricular systolic function and attenuates pathological remodelling following chronic myocardial infarction. Life Sciences, 2022, 289, 120220.	4.3	1
2	Aryl Hydrocarbon Receptor Inhibition Restores Indoxyl Sulfate-Mediated Endothelial Dysfunction in Rat Aortic Rings. Toxins, 2022, 14, 100.	3.4	13
3	Transcriptomic analysis of choroidal neovascularization reveals dysregulation of immune and fibrosis pathways that are attenuated by a novel anti-fibrotic treatment. Scientific Reports, 2022, 12, 859.	3.3	5
4	RE: Inhibition of apoptosis signal-regulating kinase 1 might be a novel therapeutic target in the treatment of cardiorenal syndrome. International Journal of Cardiology, 2021, 323, 260.	1.7	0
5	Î²-blockade prevents coronary macro- and microvascular dysfunction induced by a high salt diet and insulin resistance in the Gotoâ€“Kakizaki rat. Clinical Science, 2021, 135, 327-346.	4.3	3
6	RE: Blockade of apoptosis signal-regulating kinase 1 ameliorates cardiac dysfunction in cardiorenal syndrome via enhancing angiogenesis. International Journal of Cardiology, 2021, 326, 156.	1.7	0
7	Apoptosis signal-regulating kinase 1 inhibition reverses deleterious indoxyl sulfate-mediated endothelial effects. Life Sciences, 2021, 272, 119267.	4.3	7
8	Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers. Science Translational Medicine, 2021, 13, eabd5524.	12.4	62
9	The effect of dihydroceramide desaturase 1 inhibition on endothelial impairment induced by indoxyl sulfate. Vascular Pharmacology, 2021, 141, 106923.	2.1	4
10	RE: ASK1, a new target in treating cardiorenal syndrome (CRS). International Journal of Cardiology, 2020, 316, 207.	1.7	0
11	Cardiorenal syndrome: Multiâ€organ dysfunction involving the heart, kidney and vasculature. British Journal of Pharmacology, 2020, 177, 2906-2922.	5.4	46
12	Inhibition of apoptosis signal-regulating kinase 1 ameliorates left ventricular dysfunction by reducing hypertrophy and fibrosis in a rat model of cardiorenal syndrome. International Journal of Cardiology, 2020, 310, 128-136.	1.7	10
13	Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat. Physiological Reports, 2020, 8, e14448.	1.7	7
14	Diastolic dysfunction is initiated by cardiomyocyte impairment ahead of endothelial dysfunction due to increased oxidative stress and inflammation in an experimental prediabetes model. Journal of Molecular and Cellular Cardiology, 2019, 137, 119-131.	1.9	27
15	Prescription of physical activity in the management of high blood pressure in Australian general practices. Journal of Human Hypertension, 2019, 33, 50-56.	2.2	3
16	The role of dihydrosphingolipids in disease. Cellular and Molecular Life Sciences, 2019, 76, 1107-1134.	5.4	31
17	Inhibition of Apoptosis Signal-Regulating Kinase 1 Attenuates Myocyte Hypertrophy and Fibroblast Collagen Synthesis. Heart Lung and Circulation, 2019, 28, 495-504.	0.4	9
18	Nitrosative Stress as a Modulator of Inflammatory Change in a Model of Takotsubo Syndrome. JACC Basic To Translational Science, 2018, 3, 213-226.	4.1	36

#	Article	IF	Citations
19	Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction. International Journal of Cardiology, 2018, 258, 192-198.	1.7	48
20	Chronic kidney disease with comorbid cardiac dysfunction exacerbates cardiac and renal damage. Journal of Cellular and Molecular Medicine, 2018, 22, 628-645.	3.6	6
21	Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario. American Journal of Hypertension, 2018, 31, 1156-1163.	2.0	23
22	Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development. Future Cardiology, 2017, 13, 103-115.	1.2	1
23	Cardiac fibrosis in the ageing heart: Contributors and mechanisms. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 55-63.	1.9	60
24	Widespread Coronary Dysfunction in the Absence of HDL Receptor SR-B1 in an Ischemic Cardiomyopathy Mouse Model. Scientific Reports, 2017, 7, 18108.	3.3	20
25	Chronic intermittent hypoxia accelerates coronary microcirculatory dysfunction in insulin-resistant Goto-Kakizaki rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 311, R426-R439.	1.8	18
26	Renal cellular hypoxia in adenineâ€induced chronic kidney disease. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 896-905.	1.9	17
27	Thioredoxin interacting protein (TXNIP) regulates tubular autophagy and mitophagy in diabetic nephropathy through the mTOR signaling pathway. Scientific Reports, 2016, 6, 29196.	3.3	106
28	Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension. Cardiovascular Diabetology, 2015, 14, 92.	6.8	14
29	Cardiac Repair With a Novel Population of Mesenchymal Stem Cells Resident in the Human Heart. Stem Cells, 2015, 33, 3100-3113.	3.2	53
30	Functional Interaction between Angiotensin II Receptor Type 1 and Chemokine (C-C Motif) Receptor 2 with Implications for Chronic Kidney Disease. PLoS ONE, 2015, 10, e0119803.	2.5	42
31	Contribution of microRNA to pathological fibrosis in cardio-renal syndrome: impact of uremic toxins. Physiological Reports, 2015, 3, e12371.	1.7	27
32	Calibrated integrated backscatter and myocardial fibrosis in patients undergoing cardiac surgery. Open Heart, 2015, 2, e000278.	2.3	15
33	Thioredoxin-Interacting Protein: A Potential Therapeutic Target for Treatment of Progressive Fibrosis in Diabetic Nephropathy. Nephron, 2015, 129, 109-127.	1.8	25
34	Chloride channel ClC-5 binds to aspartyl aminopeptidase to regulate renal albumin endocytosis. American Journal of Physiology - Renal Physiology, 2015, 308, F784-F792.	2.7	8
35	Elevated cannabinoid receptor 1 and G proteinâ€coupled receptor 55 expression in proximal tubule cells and whole kidney exposed to diabetic conditions. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 256-262.	1.9	34
36	Combination therapy of mesenchymal stem cells and serelaxin effectively attenuates renal fibrosis in obstructive nephropathy. FASEB Journal, 2015, 29, 540-553.	0.5	70

#	Article	IF	Citations
37	FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy. PLoS ONE, 2015, 10, e0134392.	2.5	14
38	Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy. World Journal of Diabetes, 2015, 6, 943.	3.5	50
39	Rho Kinase Inhibition Improves Cardiac Crossâ€Bridge Dynamics in Early Diabetic Cardiomyopathy. FASEB Journal, 2015, 29, 799.7.	0.5	0
40	SDF-1/CXCR4 Signaling Preserves Microvascular Integrity and Renal Function in Chronic Kidney Disease. PLoS ONE, 2014, 9, e92227.	2.5	39
41	Impaired cardiac anti-oxidant activity in diabetes: human and correlative experimental studies. Acta Diabetologica, 2014, 51, 771-782.	2.5	11
42	High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. Cardiovascular Diabetology, 2014, 13, 89.	6.8	108
43	Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction. International Journal of Cardiology, 2013, 167, 210-219.	1.7	40
44	Role of the EGF receptor in PPARÎ³-mediated sodium and water transport in human proximal tubule cells. Diabetologia, 2013, 56, 1174-1182.	6.3	12
45	Attenuation of Armanniâ€“Ebstein lesions in a rat model of diabetes by a new anti-fibrotic, anti-inflammatory agent, FT011. Diabetologia, 2013, 56, 675-679.	6.3	16
46	Subtotal nephrectomy accelerates pathological cardiac remodeling post-myocardial infarction: Implications for cardiorenal syndrome. International Journal of Cardiology, 2013, 168, 1866-1880.	1.7	37
47	3â€²,4â€²-Bis-difluoromethoxycinnamoylanthranilate (FT061): An orally-active antifibrotic agent that reduces albuminuria in a rat model of progressive diabetic nephropathy. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6868-6873.	2.2	16
48	Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation. Cardiovascular Diabetology, 2013, 12, 111.	6.8	33
49	A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction. International Journal of Cardiology, 2013, 168, 1174-1185.	1.7	11
50	Combination Angiotensin Converting Enzyme and Direct Renin Inhibition in Heart Failure following Experimental Myocardial Infarction. Cardiovascular Therapeutics, 2013, 31, 84-91.	2.5	12
51	Obesity results in progressive atrial structural and electrical remodeling: Implications for atrial fibrillation. Heart Rhythm, 2013, 10, 90-100.	0.7	314
52	Early and Delayed Tranilast Treatment Reduces Pathological Fibrosis Following Myocardial Infarction. Heart Lung and Circulation, 2013, 22, 122-132.	0.4	28
53	Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. International Journal of Cardiology, 2013, 167, 1027-1037.	1.7	21
54	Myosin Heads Are Displaced from Actin Filaments in the In Situ Beating Rat Heart in Early Diabetes. Biophysical Journal, 2013, 104, 1065-1072.	0.5	16

#	Article	IF	Citations
55	Role of the eNOS-NO System in Regulating the Antiproteinuric Effects of VEGF Receptor 2 Inhibition in Diabetes. BioMed Research International, 2013, 2013, 1-8.	1.9	12
56	Urotensin II and the kidney. Current Opinion in Nephrology and Hypertension, 2013, 22, 107-112.	2.0	7
57	Cannabinoid Receptor 2 Expression in Human Proximal Tubule Cells is Regulated by Albumin Independent of ERK1/2 Signaling. Cellular Physiology and Biochemistry, 2013, 32, 1309-1319.	1.6	24
58	Atrial Arrhythmia in Ageing Spontaneously Hypertensive Rats: Unraveling the Substrate in Hypertension and Ageing. PLoS ONE, 2013, 8, e72416.	2.5	81
59	Obesity Is Associated with Lower Coronary Microvascular Density. PLoS ONE, 2013, 8, e81798.	2.5	45
60	The Uremic Toxin Adsorbent AST-120 Abrogates Cardiorenal Injury Following Myocardial Infarction. PLoS ONE, 2013, 8, e83687.	2.5	30
61	The Anti-fibrotic Hormone Relaxin is not Reno-protective, Despite Being Active, in an Experimental Model of Type 1 Diabetes. Protein and Peptide Letters, 2013, 20, 1029-1038.	0.9	17
62	Dynamic Synchrotron Imaging of Diabetic Rat Coronary Microcirculation In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 370-377.	2.4	37
63	eNOS Deficiency Predisposes Podocytes to Injury in Diabetes. Journal of the American Society of Nephrology: JASN, 2012, 23, 1810-1823.	6.1	124
64	Cardiorenal Syndrome. Circulation Research, 2012, 111, 1470-1483.	4.5	150
65	Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H1884-H1893.	3.2	71
66	Targeting Fibrosis for the Treatment of Heart Failure: A Role for Transforming Growth Factorâ€Î². Cardiovascular Therapeutics, 2012, 30, e30-40.	2.5	112
67	Diastolic Dysfunction of Aging Is Independent of Myocardial Structure but Associated with Plasma Advanced Glycation End-Product Levels. PLoS ONE, 2012, 7, e49813.	2.5	44
68	FT011, a new antiâ€fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy. European Journal of Heart Failure, 2012, 14, 549-562.	7.1	36
69	Cardiorenal syndrome: Pathophysiology, preclinical models, management and potential role of uraemic toxins. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 692-700.	1.9	18
70	<scp>FT</scp>23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 650-656.	1.9	16
71	Chronic Kidney Disease-Induced Cardiac Fibrosis Is Ameliorated by Reducing Circulating Levels of a Non-Dialysable Uremic Toxin, Indoxyl Sulfate. PLoS ONE, 2012, 7, e41281.	2.5	138
72	A Purpose-Synthesised Anti-Fibrotic Agent Attenuates Experimental Kidney Diseases in the Rat. PLoS ONE, 2012, 7, e47160.	2.5	37

#	Article	IF	Citations
73	Differences in Myocardial Structure and Coronary Microvasculature Between Men and Women With Coronary Artery Disease. Hypertension, 2011, 57, 186-192.	2.7	45
74	Atrial protective effects of n-3 polyunsaturated fatty acids: A long-term study in ovine chronic heart failure. Heart Rhythm, 2011, 8, 575-582.	0.7	27
75	Long-Term Administration of the Histone Deacetylase Inhibitor Vorinostat Attenuates Renal Injury in Experimental Diabetes through an Endothelial Nitric Oxide Synthase-Dependent Mechanism. American Journal of Pathology, 2011, 178, 2205-2214.	3.8	134
76	The roles of Kruppel-like factor 6 and peroxisome proliferator-activated receptor-Î³ in the regulation of macrophage inflammatory protein-3Î± at early onset of diabetes. International Journal of Biochemistry and Cell Biology, 2011, 43, 383-392.	2.8	26
77	3â€²,4â€²-Dihydroxyflavonol Antioxidant Attenuates Diastolic Dysfunction and Cardiac Remodeling in Streptozotocin-Induced Diabetic m(Ren2)27 Rats. PLoS ONE, 2011, 6, e22777.	2.5	23
78	The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy. Journal of Hypertension, 2011, 29, 1175-1184.	0.5	37
79	Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Nephrology, 2011, 16, 573-581.	1.6	54
80	Protein kinase C ÃŸ inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Nephrology, 2011, 16, no-no.	1.6	4
81	Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart. Clinical and Experimental Pharmacology and Physiology, 2011, 38, 623-631.	1.9	23
82	Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. British Journal of Pharmacology, 2011, 162, 722-732.	5.4	35
83	Therapeutic effects of human STROâ€3â€selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia. Journal of Cellular and Molecular Medicine, 2011, 15, 2117-2129.	3.6	46
84	Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. Cardiovascular Diabetology, 2011, 10, 80.	6.8	47
85	Tranilast attenuates the up-regulation of thioredoxin-interacting protein and oxidative stress in an experimental model of diabetic nephropathy. Nephrology Dialysis Transplantation, 2011, 26, 100-110.	0.7	39
86	Predictors of Atrial Fibrosis in an Ovine Model of Obesity. Journal of Arrhythmia, 2011, 27, OP44_2.	1.2	0
87	Obesity and Atrial Fibrillation: A Chronic Ovine Study. Journal of Arrhythmia, 2011, 27, YIAB_1.	1.2	0
88	Increased tissue kallikrein levels in type 2 diabetes. Diabetologia, 2010, 53, 779-785.	6.3	33
89	Microglia activation in the hypothalamic PVN following myocardial infarction. Brain Research, 2010, 1326, 96-104.	2.2	75
90	Atrial Remodeling in an Ovine Model of Anthracycline-Induced Nonischemic Cardiomyopathy: Remodeling of the Same Sort. Journal of Cardiovascular Electrophysiology, 2010, 22, no-no.	1.7	32

#	Article	IF	Citations
91	Culture-Modified Bone Marrow Cells Attenuate Cardiac and Renal Injury in a Chronic Kidney Disease Rat Model via a Novel Antifibrotic Mechanism. PLoS ONE, 2010, 5, e9543.	2.5	55
92	Characterization of cardiac remodeling in a large animal â€œone-kidney, one-clipâ€•hypertensive model. Blood Pressure, 2010, 19, 119-125.	1.5	17
93	Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H1415-H1425.	3.2	106
94	Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?. European Heart Journal, 2010, 31, 1771-1779.	2.2	256
95	Hypertension and atrial fibrillation: Evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Heart Rhythm, 2010, 7, 1282-1290.	0.7	168
96	Short-term hypertension is associated with the development of atrial fibrillation substrate: A study in an ovine hypertensive model. Heart Rhythm, 2010, 7, 396-404.	0.7	90
97	Effect of Atorvastatin on Cardiac Remodelling and Mortality in Rats Following Hyperglycemia and Myocardial Infarction. International Journal of Cardiology, 2010, 143, 353-360.	1.7	7
98	Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy. Peptides, 2010, 31, 1523-1530.	2.4	16
99	Expression, Localization, and Function of the Thioredoxin System in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2009, 20, 730-741.	6.1	96
100	PKC-Î²1 Mediates Glucose-Induced Akt Activation and TGF-Î²1 Upregulation in Mesangial Cells. Journal of the American Society of Nephrology: JASN, 2009, 20, 554-566.	6.1	100
101	BK virus RNA can be detected in archival renal transplant biopsies using the reverse trancription polymerase chain reaction. Nephrology Dialysis Transplantation, 2009, 24, 661-666.	0.7	3
102	Protein kinase C-Â inhibition attenuates the progression of nephropathy in non-diabetic kidney disease. Nephrology Dialysis Transplantation, 2009, 24, 1782-1790.	0.7	21
103	Inhibition of Protein Kinase Câ€“Î² by Ruboxistaurin Preserves Cardiac Function and Reduces Extracellular Matrix Production in Diabetic Cardiomyopathy. Circulation: Heart Failure, 2009, 2, 129-137.	3.9	106
104	The (Pro)Renin Receptor. Hypertension, 2009, 54, 261-269.	2.7	234
105	Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 7003-7006.	2.2	44
106	High glucose induced endothelial cell growth inhibition is associated with an increase in TGFÎ²1 secretion and inhibition of Ras prenylation via suppression of the mevalonate pathway. International Journal of Biochemistry and Cell Biology, 2009, 41, 561-569.	2.8	4
107	Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?. Kidney International, 2009, 76, 23-31.	5.2	35
108	Transcription Factors KrÃ¼ppel-Like Factor 6 and Peroxisome Proliferator-Activated Receptor-Î³ Mediate High Glucose-Induced Thioredoxin-Interacting Protein. American Journal of Pathology, 2009, 175, 1858-1867.	3.8	48

#	Article	IF	Citations
109	Role of Statins in Diabetes Complications. Current Diabetes Reviews, 2009, 5, 165-170.	1.3	9
110	Increased renal gene transcription of protein kinase C-Î² in human diabetic nephropathy: relationship to long-term glycaemic control. Diabetologia, 2008, 51, 668-674.	6.3	38
111	Perindopril attenuates tubular hypoxia and inflammation in an experimental model of diabetic nephropathy in transgenic Renâ€2 rats. Nephrology, 2008, 13, 721-729.	1.6	9
112	Vitamin D2 supplementation induces the development of aortic stenosis in rabbits: Interactions with endothelial function and thioredoxin-interacting protein. European Journal of Pharmacology, 2008, 590, 290-296.	3.5	37
113	Tranilast Ameliorates Experimental Mesangial Proliferative Glomerulonephritis. Nephron Experimental Nephrology, 2008, 109, e1-e7.	2.2	8
114	Role of KrÃ¼ppel-like factor 6 in transforming growth factor-Î²1-induced epithelial-mesenchymal transition of proximal tubule cells. American Journal of Physiology - Renal Physiology, 2008, 295, F1388-F1396.	2.7	76
115	Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H1804-H1814.	3.2	98
116	In vivo visualization of albumin degradation in the proximal tubule. Kidney International, 2008, 74, 1480-1486.	5.2	33
117	Relaxin Ameliorates Fibrosis in Experimental Diabetic Cardiomyopathy. Endocrinology, 2008, 149, 3286-3293.	2.8	80
118	Clinically Relevant Models of Diabetic Cardiac Complications. Circulation Research, 2007, 101, e78.	4.5	9
119	Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2860-H2869.	3.2	54
120	Effects on protein kinase C-Î² inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. American Journal of Physiology - Renal Physiology, 2007, 293, F565-F574.	2.7	30
121	Angiotensin II and the Cardiac Complications of Diabetes Mellitus. Current Pharmaceutical Design, 2007, 13, 2721-2729.	1.9	22
122	Progressive diabetic nephropathy in the Ren-2 rat. American Journal of Physiology - Renal Physiology, 2007, 292, F1662-F1662.	2.7	4
123	Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovascular Research, 2007, 76, 280-291.	3.8	72
124	High glucose induces macrophage inflammatory protein-3Â in renal proximal tubule cells via a transforming growth factor-Â1 dependent mechanism. Nephrology Dialysis Transplantation, 2007, 22, 3147-3153.	0.7	34
125	Advanced glycation end products decrease mesangial cell MMP-7: A role in matrix accumulation in diabetic nephropathy?. Kidney International, 2007, 72, 481-488.	5.2	48
126	Macrophage Infiltration and Cellular Proliferation in the Non-Ischemic Kidney and Heart following Prolonged Unilateral Renal Ischemia. Nephron Physiology, 2007, 106, p54-p62.	1.2	47

#	Article	IF	Citations
127	Effect of Ruboxistaurin on Urinary Transforming Growth Factor-Â in Patients With Diabetic Nephropathy and Type 2 Diabetes. Diabetes Care, 2007, 30, 995-996.	8.6	50
128	Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14448-14453.	7.1	137
129	High Glucose-Induced Thioredoxin-Interacting Protein in Renal Proximal Tubule Cells Is Independent of Transforming Growth Factor-Î²1. American Journal of Pathology, 2007, 171, 744-754.	3.8	71
130	The differential regulation of Smad7 in kidney tubule cells by connective tissue growth factor and transforming growth factor-beta1. Nephrology, 2007, 12, 267-274.	1.6	16
131	Diabetic nephropathy without the diabetes: If not hyperglycaemia, then what? (Editorial). Nephrology, 2007, 12, 67-68.	1.6	0
132	Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia, 2007, 50, 2398-2404.	6.3	165
133	Glucose transporters in animal models of diabetes and hypertension. American Journal of Physiology - Renal Physiology, 2006, 291, F702-F703.	2.7	3
134	Mitogen activated protein kinase signaling in the kidney: target for intervention?. Signal Transduction, 2006, 6, 32-53.	0.4	12
135	Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model. Kidney International, 2006, 69, 1954-1960.	5.2	23
136	Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. American Journal of Physiology - Renal Physiology, 2006, 290, F205-F213.	2.7	69
137	Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 193-208.	4.5	58
138	SB-267268, a Nonpeptidic Antagonist of Î±vÎ²3and Î±vÎ²5Integrins, Reduces Angiogenesis and VEGF Expression in a Mouse Model of Retinopathy of Prematurity. , 2006, 47, 1600.		53
139	Transforming Growth Factor-Î² in Human Diabetic Nephropathy. Diabetes Care, 2006, 29, 2670-2675.	8.6	50
140	High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule. Kidney International, 2005, 68, 985-997.	5.2	71
141	Modulation of osteopontin in proteinuria-induced renal interstitial fibrosis. Journal of Pathology, 2005, 207, 483-492.	4.5	26
142	Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-?. Cardiovascular Research, 2005, 65, 694-701.	3.8	102
143	Cells expressing the stem cell factor receptor, c-kit, contribute to neoangiogenesis in diabetes. Diabetes and Vascular Disease Research, 2005, 2, 76-80.	2.0	18
144	Renin Inhibition. Hypertension, 2005, 46, 471-472.	2.7	5

#	Article	IF	Citations
145	Sandford Lloyd Skinner (1933â€“2005). Hypertension, 2005, 46, 452-453.	2.7	0
146	Neonatal calyceal dilation and renal fibrosis resulting from loss of Adamts-1 in mouse kidney is due to a developmental dysgenesis. Nephrology Dialysis Transplantation, 2005, 20, 419-423.	0.7	31
147	Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. Journal of Molecular and Cellular Cardiology, 2005, 39, 213-221.	1.9	70
148	Protein Kinase CÎ² Inhibition Attenuates Osteopontin Expression, Macrophage Recruitment, and Tubulointerstitial Injury in Advanced Experimental Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2005, 16, 1654-1660.	6.1	84
149	Platelet-Derived Growth Factor Receptor Transactivation Mediates the Trophic Effects of Angiotensin II In Vivo. Hypertension, 2004, 44, 195-202.	2.7	52
150	Tranilast Attenuates Structural and Functional Aspects of Renal Injury in the Remnant Kidney Model. Journal of the American Society of Nephrology: JASN, 2004, 15, 2619-2629.	6.1	61
151	Angiotensin II influences ovarian follicle development in the transgenic (mRen-2)27 and Sprague-Dawley rat. Journal of Endocrinology, 2004, 180, 311-324.	2.6	16
152	Angiotensin II-induced proteinuria and expression of the podocyte slit pore membrane protein, nephrin. Nephrology Dialysis Transplantation, 2004, 19, 262-263.	0.7	24
153	Fas-induced apoptosis is a feature of progressive diabetic nephropathy in transgenic (mRen-2)27 rats: Attenuation with renin-angiotensin blockade. Nephrology, 2004, 9, 7-13.	1.6	24
154	Plasmin is not protective in experimental renal interstitial fibrosis1. Kidney International, 2004, 66, 68-76.	5.2	67
155	Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney International, 2004, 66, 1805-1814.	5.2	60
156	Tranilast reduces mesenteric vascular collagen deposition and chymase-positive mast cells in experimental diabetes. Journal of Diabetes and Its Complications, 2004, 18, 309-315.	2.3	37
157	Drug therapy for the cardiac complications of diabetes. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 195-200.	0.5	4
158	Inhibition of Platelet-Derived Growth Factor Promotes Pericyte Loss and Angiogenesis in Ischemic Retinopathy. American Journal of Pathology, 2004, 164, 1263-1273.	3.8	108
159	Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. American Journal of Kidney Diseases, 2004, 44, 826-831.	1.9	92
160	Vasoactive Renal Factors and the Progression of Diabetic Nephropathy. Current Pharmaceutical Design, 2004, 10, 3373-3384.	1.9	11
161	Mast cell infiltration and chemokine expression in progressive renal disease1. Kidney International, 2003, 64, 906-913.	5.2	69
162	The reninâ€“angiotensin system and the longâ€term complications of diabetes: pathophysiological and therapeutic considerations. Diabetic Medicine, 2003, 20, 607-621.	2.3	75

#	Article	IF	Citations
163	The Renin-Angiotensin System Influences Ocular Endothelial Cell Proliferation in Diabetes. American Journal of Pathology, 2003, 162, 151-160.	3.8	100
164	Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes. Diabetes and Metabolism, 2003, 29, 386-392.	2.9	27
165	Direct Actions of Urotensin II on the Heart. Circulation Research, 2003, 93, 246-253.	4.5	196
166	Over-expression of platelet-derived growth factor in human diabetic nephropathy. Nephrology Dialysis Transplantation, 2003, 18, 1392-1396.	0.7	54
167	COX-2 Inhibition and Retinal Angiogenesis in a Mouse Model of Retinopathy of Prematurity. , 2003, 44, 974.		98
168	Intervention with Tranilast Attenuates Renal Pathology and Albuminuria in Advanced Experimental Diabetic Nephropathy. Nephron Physiology, 2003, 95, p83-p91.	1.2	52
169	Protein Kinase C Î² Inhibition Attenuates the Progression of Experimental Diabetic Nephropathy in the Presence of Continued Hypertension. Diabetes, 2003, 52, 512-518.	0.6	173
170	Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease?. Nephrology Dialysis Transplantation, 2003, 18, 2293-2299.	0.7	19
171	Vascular endothelial growth factor expression and glomerular endothelial cell loss in the remnant kidney model. Nephrology Dialysis Transplantation, 2003, 18, 1286-1292.	0.7	35
172	Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrology Dialysis Transplantation, 2002, 17, 1327-1332.	0.7	109
173	Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in advanced diabetic nephropathy of transgenic (mRen-2)27 rats. Nephrology Dialysis Transplantation, 2002, 17, 985-991.	0.7	57
174	Characterisation of a thymic reninâ€“angiotensin system in the transgenic m(Ren-2)27 rat. Molecular and Cellular Endocrinology, 2002, 194, 201-209.	3.2	20
175	Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia, 2002, 45, 268-275.	6.3	118
176	Expression during rat fetal development of GLUT12 - a member of the class III hexose transporter family. Anatomy and Embryology, 2002, 205, 441-452.	1.5	48
177	Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney International, 2002, 61, 31-39.	5.2	76
178	Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia, 2002, 45, 1572-1576.	6.3	204
179	Effects of Low-Dose and Early versus Late Perindopril Treatment on the Progression of Severe Diabetic Nephropathy in (mREN-2)27 Rats. Journal of the American Society of Nephrology: JASN, 2002, 13, 684-692.	6.1	17
180	ALT-946 and Aminoguanidine, Inhibitors of Advanced Glycation, Improve Severe Nephropathy in the Diabetic Transgenic (mREN-2)27 Rat. Diabetes, 2002, 51, 3283-3289.	0.6	95

#	Article	IF	Citations
181	Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. Journal of Hepatology, 2001, 35, 376-385.	3.7	159
182	Novel approaches to the treatment of progressive renal disease. Current Opinion in Pharmacology, 2001, 1, 183-189.	3.5	11
183	PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney International, 2001, 59, 1324-1332.	5.2	108
184	Angiotensin-converting enzyme inhibition attenuates renal platelet-derived growth factor gene expression and cell proliferation in subtotal nephrectomy. Nephrology, 2001, 6, 290-297.	1.6	0
185	Nephropathy in type 2 diabetes: current therapeutic strategies. Nephrology, 2001, 6, 266-269.	1.6	2
186	Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia, 2001, 44, 878-882.	6.3	137
187	The Interaction between the Renin-Angiotensin System and Vascular Endothelial Growth Factor in the Pathogenesis of Retinal Neovascularization in Diabetes. Journal of Vascular Research, 2001, 38, 527-535.	1.4	26
188	Renoprotective and antiâ€hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRenâ€2)27 rat. Nephrology Dialysis Transplantation, 2001, 16, 1343-1349.	0.7	40
189	Aminoguanidine Ameliorates Overexpression of Prosclerotic Growth Factors and Collagen Deposition in Experimental Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2001, 12, 2098-2107.	6.1	108
190	Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney International, 2000, 57, 1882-1894.	5.2	96
191	Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney International, 2000, 58, 2437-2451.	5.2	120
192	Experimental diabetic nephropathy: Is it relevant to the human disease. Nephrology, 2000, 5, 177-185.	1.6	4
193	Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia, 2000, 43, 1360-1367.	6.3	173
194	Retinal Neovascularization Is Prevented by Blockade of the Renin-Angiotensin System. Hypertension, 2000, 36, 1099-1104.	2.7	216
195	Blockade of the Renin-Angiotensin and Endothelin Systems on Progressive Renal Injury. Hypertension, 2000, 36, 561-568.	2.7	93
196	Endothelin Receptor Antagonism Ameliorates Mast Cell Infiltration, Vascular Hypertrophy, and Epidermal Growth Factor Expression in Experimental Diabetes. Circulation Research, 2000, 86, 158-165.	4.5	72
197	SPARC Gene Expression Is Increased in Diabetes-Related Mesenteric Vascular Hypertrophy. Microvascular Research, 2000, 59, 61-71.	2.5	14
198	Protective role for Epidermal Growth Factor in Advanced Diabetic Nephropathy of Transgenic (mRenâ€2)27 rats. Nephrology, 2000, 5, A102-A102.	1.6	0

#	Article	IF	Citations
199	THE IMPORTANCE OF BLOCKADE OF THE RENIN ANGIOTENSIN AND ENDOTHELIN SYSTEMS ON PROGRESSIVE RENAL INJURY IN SUBTOTALLY NEPHRECTOMISED RATS: USE OF COMBINATION REGIMENS. Nephrology, 2000, 5, A109-A109.	1.6	0
200	Protective role for Epidermal Growth Factor in Advanced Diabetic Nephropathy of Transgenic (mRenâ€2)27 rats. Nephrology, 2000, 5, A102-A102.	1.6	0
201	Localization of Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression in the Rat Eye. Connective Tissue Research, 1999, 40, 295-303.	2.3	37
202	Increased bradykinin and â€œnormalâ€•angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. Kidney International, 1999, 56, 211-221.	5.2	52
203	Role of hyperlipidemia in progressive renal disease: Focus on diabetic nephropathy. Kidney International, 1999, 56, S31-S36.	5.2	79
204	Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes.. Diabetes, 1999, 48, 2229-2239.	0.6	446
205	Pathological Expression of Renin and Angiotensin II in the Renal Tubule after Subtotal Nephrectomy. American Journal of Pathology, 1999, 155, 429-440.	3.8	132
206	A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney International, 1998, 54, 343-352.	5.2	153
207	Renal expression of transforming growth factor-Î² inducible gene-h3 (Î²ig-h3) in normal and diabetic rats. Kidney International, 1998, 54, 1052-1062.	5.2	79
208	Adrenaline cells of the rat adrenal cortex and medulla contain renin and prorenin. Molecular and Cellular Endocrinology, 1996, 119, 175-184.	3.2	25
209	Renin processing and secretion in adrenal and retina of transgenic (mREN-2)27 rats. Kidney International, 1994, 46, 1583-1587.	5.2	23